Arcturus Therapeutics Holdings Inc（ARCT）股票分析ARCTArcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arcturus Therapeutics is a good buy right now due to its current price of $9.84, which is significantly below the analyst price target of $20, suggesting a potential upside of over 41%. Additionally, the recent positive clinical trial results for ARCT-810 have boosted investor confidence, as evidenced by a nearly 7% increase in share price following the announcement. However, the main risk is the company's ongoing losses, with a net income of -23,785,000 USD reported in Q2 2026, indicating continued financial challenges.

3 analysts cover ARCT: 1 rate it Buy, 1 Hold and 1 Sell. The average price target is 14.00.